We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AD Protective Gene Represents Promising Therapeutic Target

By LabMedica International staff writers
Posted on 14 Dec 2017
Print article
Alzheimer's disease (AD) researchers have identified a gene variant that is present in a small percentage of individuals with AD risk factors but who exhibit resilience by living well beyond 75 years of age without developing any clinical symptoms of cognitive decline.

Investigators at Brigham Young University (Salt Lake City, UT, USA) used the vast Utah Population Database of genealogical and historical medical records to identify a cohort of over 200 “AD resilient” individuals. They performed linkage analyses of the resilient individuals and then used whole genome sequences to identify candidate SNPs (single-nucleotide polymorphisms) in significant linkage regions. Next, they replicated SNPs from the linkage peaks that reduced risk for AD in an independent dataset and in a gene-based test. Finally, they experimentally characterized replicated SNPs in vitro.

Results published in the November 29, 2017, online edition of the journal Genome Medicine revealed promising variants in the RAB10 (Ras-related protein Rab-10) and SAR1A (secretion associated Ras related GTPase 1A) genes. The resilient subjects shared a variant in the RAB10 gene while those who got the disease did not share the genetic variant. The investigators also found that RAB10 expression was significantly elevated in human AD brains

The RAB10 findings were replicated in two independent series of unrelated individuals and in a gene-based test. Both RAB10 and SAR1A were differentially expressed in human AD brains. Results of in vitro tests to evaluate the biological impact of RAB10 and SAR1A suggested that RAB10 variants were linked to risk for AD, and that RAB10 may represent a promising therapeutic target for AD prevention.

"There are currently no meaningful interventions for Alzheimer disease; no prevention, no modifying therapies, no cure," said senior author Dr. John Kauwe, associate professor of biology at Brigham Young University. "The discoveries we are reporting in this manuscript provide a new target with a new mechanism that we believe has great potential to impact Alzheimer's disease in the future."

Related Links:
Brigham Young University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Ultrasound-based duplex sonography combined with a new genetic testing procedure can identify clonal haematopoiesis (Photo courtesy of 123RF)

New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk

A key interest area in cardiovascular research today is the impact of clonal hematopoiesis on cardiovascular diseases. Clonal hematopoiesis results from mutations in hematopoietic stem cells and may lead... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more